RTP Mobile Logo
Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer (Faculty Presentations)
Released September 2023

Featuring slide presentations and related discussion from Dr Hope S Rugo and Dr Tiffany Traina. Published September 29, 2023. (Faculty Presentations)

CE Information and Faculty Disclosures

    This program is intended for medical oncologists, breast surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.


    • Review available research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive metastatic triple-negative breast cancer (mTNBC), and use this information to identify patients who may be appropriate for this approach.
    • Evaluate published research, clinical factors (eg, age, performance status, prior therapeutic exposure, presence or absence of low-level HER2 expression) and personal preferences in the selection and sequencing of available therapies for patients with PD-L1-negative mTNBC or those who experience disease progression on front-line chemoimmunotherapy.
    • Assess clinical trial data with HER2-targeted therapy for patients with ER-negative, HER2-low metastatic breast cancer to determine how to optimally incorporate this therapeutic approach into current treatment algorithms.
    • Recognize the spectrum, frequency and severity of treatment-emergent adverse events with agents commonly used for mTNBC, and develop strategies to monitor for, prevent and manage these complications.
    • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for mTNBC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/InsideTheIssue2023/TNBC/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Hope S Rugo, MD
    Professor of Medicine
    Winterhof Family Professor of Breast Cancer
    Director, Breast Oncology and Clinical Trials Education
    Medical Director, Cancer Infusion Services
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Consultancy/Advisory Support: Daiichi Sankyo Inc, Napo Pharmaceuticals Inc, Puma Biotechnology Inc, Viatris; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc, Taiho Oncology Inc, Veru Inc; Travel Support to Academic Meetings: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Merck.

    Tiffany A Traina, MD, FASCO
    Vice Chair, Department of Medicine
    Section Head, Triple-Negative Breast Cancer Clinical Research Program
    Associate Attending Physician
    Breast Medicine Service
    Memorial Sloan Kettering Cancer Center
    Associate Professor
    Weill Cornell Medical College
    New York, New York

    Consulting or Advisory Role: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, G1 Therapeutics Inc, GE Healthcare, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Hengrui Therapeutics Inc, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc, TerSera Therapeutics LLC; Research Funding (to Institution): Astellas, AstraZeneca Pharmaceuticals LP, Ayala Pharmaceuticals, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Gilead Sciences Inc and Merck.

    Release date: September 2023
    Expiration date: September 2024

    After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):